Aside from FLT3/NPM1, TP53 was the most prevalent mutation and only seen in those without a response, 4/31 (13%): all 4 patients had FLT3 WT/ NPM1 WT (wild type) and unfavorable karyotypes (highlighted in blue in Table 3), while only 1/4 (25%) had de novo AML. Here, TP53 is linked to acute myeloid leukemia.